HLA anchor optimization of the Melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells

Journal of Immunology

Volumn 188, Issue 5, 2012, Pages 2102-2110

  Chauvin, Joë Marc ^a,b   Larrieu, Pierre ^b,c   Sarrabayrouse, Guillaume ^a,b   Prévost Blondel, Armelle ^d,e   Lengagne, Renée ^d,e   Desfrançois, Juliette ^a,b,f   Labarrière, Nathalie ^a,b   Jotereau, Francine ^a,b,g  

^a INSERM   (France)

^b CNRS   (France)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d INSTITUT COCHIN   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Plateforme de Cytométrie de l'Institut Fédératif de Recherche 26   (France)

^g UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MELAN A; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; COLORECTAL NEOPLASMS; CROSS-PRIMING; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MART-1 ANTIGEN; MELANOMA; MICE; MICE, MUTANT STRAINS; MOLECULAR SEQUENCE DATA; MONOCYTES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84857465746     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101807     Document Type: Article

References (37)

1. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647. (Pubitemid 21917508)
2. Rosenberg, S. A., and M. E. Dudley. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101(Suppl 2): 14639-14645. (Pubitemid 39346736)
3. Melief, C. J., and S. H. van der Burg. 2008. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8: 351-360. (Pubitemid 351589701)
4. Chen, J. L., P. R. Dunbar, U. Gileadi, E. Jäger, S. Gnjatic, Y. Nagata, E. Stockert, D. L. Panicali, Y. T. Chen, A. Knuth, et al. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165: 948-955. (Pubitemid 30484763)
5. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327. (Pubitemid 28144091)
6. Valmori, D., V. Dutoit, D. Liénard, D. Rimoldi, M. J. Pittet, P. Champagne, K. Ellefsen, U. Sahin, D. Speiser, F. Lejeune, et al. 2000. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60: 4499-4506. (Pubitemid 32103631)
7. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758. (Pubitemid 28110836)
8. Iero, M., P. Filipazzi, C. Castelli, F. Belli, R. Valdagni, G. Parmiani, R. Patuzzo, M. Santinami, and L. Rivoltini. 2009. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol. Immunother. 58: 1159-1167.
9. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 105: 3849-3854. (Pubitemid 351723488)
10. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, R. Offringa, and S. H. van der Burg. 2007. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179: 5033-5040.
11. Faure, F., A. Mantegazza, C. Sadaka, C. Sedlik, F. Jotereau, and S. Amigorena. 2009. Long-lasting cross-presentation of tumor antigen in human DC. Eur. J. Immunol. 39: 380-390.
12. Kast, W. M., L. Roux, J. Curren, H. J. Blom, A. C. Voordouw, R. H. Meloen, D. Kolakofsky, and C. J. Melief. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88: 2283-2287. (Pubitemid 21916400)
13. Benlalam, H., V. Vignard, A. Khammari, A. Bonnin, Y. Godet, M. C. Pandolfino, F. Jotereau, B. Dreno, and N. Labarrière. 2007. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol. Immunother. 56: 515-526. (Pubitemid 46204537)
14. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
15. Khammari, A., N. Labarrière, V. Vignard, J. M. Nguyen, M. C. Pandolfino, A. C. Knol, G. Quéreux, S. Saiagh, A. Brocard, F. Jotereau, and B. Dreno. 2009. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. 129: 2835-2842.
16. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
17. Vignard, V., B. Lemercier, A. Lim, M. C. Pandolfino, Y. Guilloux, A. Khammari, C. Rabu, K. Echasserieau, F. Lang, M. L. Gougeon, et al. 2005. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 175: 4797-4805. (Pubitemid 41362023)
18. Alanio, C., F. Lemaitre, H. K. Law, M. Hasan, and M. L. Albert. 2010. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 115: 3718-3725.
19. Gervois, N., Y. Guilloux, E. Diez, and F. Jotereau. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHCtumor peptide interactions. J. Exp. Med. 183: 2403-2407. (Pubitemid 26158935)
20. Bodinier, M., M. A. Peyrat, C. Tournay, F. Davodeau, F. Romagne, M. Bonneville, and F. Lang. 2000. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat. Med. 6: 707-710. (Pubitemid 30398798)
21. Newberg, M. H., D. H. Smith, S. B. Haertel, D. R. Vining, E. Lacy, and V. H. Engelhard. 1996. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156: 2473-2480. (Pubitemid 26091573)
22. Derré, L., M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Lévy, and D. E. Speiser. 2007. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J. Immunol. 179: 7635-7645.
23. Valmori, D., J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar, D. Liénard, D. Rimoldi, V. Cerundolo, F. Jotereau, J. C. Cerottini, et al. 1999. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11: 1971-1980.
24. Mempel, T. R., S. E. Henrickson, and U. H. Von Andrian. 2004. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427: 154-159. (Pubitemid 38094955)
25. Chen, J. L., G. Stewart-Jones, G. Bossi, N. M. Lissin, L. Wooldridge, E. M. Choi, G. Held, P. R. Dunbar, R. M. Esnouf, M. Sami, et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201: 1243-1255. (Pubitemid 40629068)
26. Bioley, G., C. Jandus, S. Tuyaerts, D. Rimoldi, W. W. Kwok, D. E. Speiser, J. M. Tiercy, K. Thielemans, J. C. Cerottini, and P. Romero. 2006. Melan-A/ MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J. Immunol. 177: 6769-6779. (Pubitemid 44715041)
27. León, B., M. López-Bravo, and C. Ardavín. 2007. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26: 519-531. (Pubitemid 46602998)
28. Mouriès, J., G. Moron, G. Schlecht, N. Escriou, G. Dadaglio, and C. Leclerc. 2008. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112: 3713-3722.
29. Dutoit, V., V. Rubio-Godoy, M. J. Pittet, A. Zippelius, P. Y. Dietrich, F. A. Legal, P. Guillaume, P. Romero, J. C. Cerottini, R. A. Houghten, et al. 2002. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J. Exp. Med. 196: 207-216. (Pubitemid 34787510)
30. Pittet, M. J., A. Zippelius, D. Valmori, D. E. Speiser, J. C. Cerottini, and P. Romero. 2002. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 23: 325-328. (Pubitemid 34717898)
31. Ayyoub, M., A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J. C. Cerottini, P. Romero, F. Lejeune, D. Liénard, and D. E. Speiser. 2003. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin. Cancer Res. 9: 669-677. (Pubitemid 36182599)
32. van der Burg, S. H., and C. J. Melief. 2011. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 23: 252-257.
33. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
34. Welters, M. J., G. G. Kenter, P. J. de Vos van Steenwijk, M. J. Löwik, D. M. Berends-van der Meer, F. Essahsah, L. F. Stynenbosch, A. P. Vloon, T. H. Ramwadhdoebe, S. J. Piersma, et al. 2010. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. USA 107: 11895-11899.
35. Rosenberg, S. A., and M. E. Dudley. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21: 233-240.
36. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, K. E. Morton, C. M. Laurencot, S. M. Steinberg, D. E. White, and M. E. Dudley. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
37. Kotturi, M. F., I. Scott, T. Wolfe, B. Peters, J. Sidney, H. Cheroutre, M. G. von Herrath, M. J. Buchmeier, H. Grey, and A. Sette. 2008. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J. Immunol. 181: 2124-2133.